+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Progesterone Market by Product Type, Indication, Route of Administration, End User - Global Forecast to 2030- Product Image
Progesterone Market by Product Type, Indication, Route of Administration, End User - Global Forecast to 2030- Product Image
Sale

Progesterone Market by Product Type, Indication, Route of Administration, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5925110
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Progesterone Market grew from USD 1.47 billion in 2024 to USD 1.68 billion in 2025. It is expected to continue growing at a CAGR of 13.50%, reaching USD 3.15 billion by 2030.

Unveiling the Progesterone Market Landscape

The global progesterone market has emerged as a focal point for healthcare stakeholders, reflecting the compound’s multifaceted roles in reproductive health, hormone replacement therapy, and emerging clinical indications. In recent years, evolving regulatory frameworks, expanding therapeutic applications, and heightened awareness of women’s health issues have converged to elevate the importance of progesterone-based therapies. As an endogenous hormone with critical functions in maintaining pregnancy and regulating menstrual cycles, progesterone serves as both a therapeutic agent and a research focus for novel drug delivery systems.

Against this backdrop, manufacturers and investors are closely monitoring shifts in raw material sourcing, patent landscapes, and formulation innovations. Natural progesterone continues to appeal to segments prioritizing bioidentical hormone therapy, while advances in synthetic analogues address stability and cost considerations. Meanwhile, breakthroughs in route of administration-from injectable depots to transdermal patches-are unlocking new patient adherence strategies. These developments underscore the need for an integrated view of supply chain dynamics, regulatory approvals, and clinical trial outcomes. By setting the stage with a holistic overview of market drivers, competitive forces, and demographic trends, this summary provides executives with the insights required to navigate a rapidly transforming environment.

Charting Revolutionary Shifts in Progesterone Therapy

The progesterone industry is undergoing transformative shifts driven by breakthroughs in personalized medicine, digital therapeutics, and advanced manufacturing technologies. Precision dosing platforms now enable clinicians to tailor hormone levels with unprecedented accuracy, optimizing efficacy and minimizing adverse events. Simultaneously, the integration of digital health solutions-such as mobile monitoring apps and wearable sensors-facilitates real-time tracking of hormone therapy adherence and patient outcomes.

On the manufacturing front, continuous flow chemistry and biocatalytic processes are redefining production efficiency, reducing batch variability and environmental impact. These technological leaps are complemented by a surge in novel delivery formats that enhance bioavailability, including nanoparticle-based transdermal systems and bioresorbable implants. In parallel, regulatory agencies are streamlining approval pathways for biosimilars and generic formulations, intensifying competition and broadening market access. Consequently, industry players are forging strategic alliances to co-develop proprietary platforms and expand global footprints. Taken together, these developments herald a new era in progesterone therapy, where innovation cycles are shorter, patient engagement is deeper, and value creation is more closely aligned with clinical outcomes.

Assessing the Ripple Effects of 2025 Tariff Adjustments

In 2025, the implementation of revised United States tariffs on pharmaceutical intermediates and finished formulations has sent ripples throughout the progesterone supply chain. An increase in levies on raw precursors imported from key manufacturing hubs has elevated input costs for both natural and synthetic progesterone producers. This has led some contract manufacturers to renegotiate long-term supply contracts, while others are exploring nearshoring alternatives to mitigate exposure to import duties.

The impact extends beyond cost inflation, as end users in hospital and clinic settings face reimbursement pressures that constrain pricing flexibility. In response, several organizations have accelerated the adoption of process intensification techniques and sought tariff exclusions for high-purity active pharmaceutical ingredients. Meanwhile, downstream distributors are optimizing inventory strategies to smooth cash flow and avoid stockouts. Despite these headwinds, opportunities have emerged for agile players capable of leveraging domestic production incentives and supply chain resilience as differentiators. Ultimately, the 2025 tariff landscape will serve as a catalyst for strategic realignment and operational innovation across the progesterone sector.

Decoding Market Segmentation for Strategic Growth

Gaining clarity on market segmentation is essential for identifying high-growth niches and aligning resources with the most promising opportunities. When categorizing the landscape by product type, two main categories emerge: natural progesterone favored for bioidentical hormone replacement, and synthetic progesterone encompassing established analogues such as medroxyprogesterone acetate and norethisterone. In the realm of therapeutic application, the market divides into contraceptives-with combined oral contraceptives and progestin-only pills-fertility treatments composed of assisted reproductive technologies and ovulation induction protocols, and hormone replacement therapies targeting endometrial protection and menopause management.

Routes of administration further refine strategic focus, spanning injectable options delivered via intramuscular or subcutaneous injection, oral tablets, transdermal patches, and vaginal formulations including gels, suppositories, and tablets. Finally, end users split into clinical environments such as outpatient clinics and hospitals, alongside home healthcare settings where self-administered regimens are gaining acceptance. By mapping these interlocking segments, stakeholders can pinpoint underserved patient populations, optimize go-to-market approaches, and calibrate investment in R&D to match evolving clinical and consumer demands.

Regional Dynamics Shaping Progesterone Adoption

Regional performance in the progesterone market reflects diverse regulatory climates, healthcare infrastructures, and demographic trends. In the Americas, robust research funding and widespread insurance coverage support rapid innovation adoption, particularly in hormone replacement therapy and fertility treatment segments. Regulatory pathways are well-established, enabling efficient approval of generics and novel delivery systems, while patient advocacy groups bolster education and access initiatives.

Europe, the Middle East, and Africa present a mosaic of regulatory regimes, from centralized European Medicines Agency frameworks to country-specific registration requirements. Established pharmaceutical hubs in Western Europe coexist with emerging markets in Eastern Europe and the Gulf, where rising disposable incomes and expanding clinic networks spur growth. In Africa, public-private partnerships seek to enhance reproductive health services, creating nascent demand for both contraceptive and fertility-related progesterone therapies.

Asia-Pacific stands out for its cost-sensitive manufacturing ecosystems and rapidly growing patient populations. Regulatory harmonization efforts, such as the ASEAN Common Technical Dossier, are streamlining approvals, while domestic producers are scaling capacity to serve both regional and global markets. Demographic shifts-including declining fertility rates and aging populations-are driving increased utilization of hormone replacement therapy, signaling long-term opportunities for tailored progesterone solutions.

Competitive Forces Defining Market Leadership

Key players in the progesterone market are leveraging innovation, strategic alliances, and geographic expansion to consolidate their positions. Leading pharmaceutical companies are advancing proprietary delivery platforms, filing patents on novel formulations, and investing in clinical trials that explore new indications. Collaborative partnerships between established drugmakers and biotech firms are accelerating the translation of laboratory breakthroughs into commercial offerings. Several organizations have also pursued strategic acquisitions to augment their biosynthesis capabilities and broaden their product portfolios.

In parallel, contract development and manufacturing organizations are differentiating through specialized services, such as hormone assay validation and process development for high-purity active ingredients. Meanwhile, niche innovators are focusing on digital health integration, launching companion apps that optimize treatment adherence and patient monitoring. Competitive dynamics are further shaped by evolving pricing pressures, as generic entrants challenge brand-name premiums across both contraceptive and hormone replacement segments. Companies that can seamlessly combine cost-effective production with clinical differentiation and supply chain resilience are positioning themselves for sustainable leadership in this rapidly evolving environment.

Strategic Imperatives for Forward-Thinking Executives

To thrive in the evolving progesterone landscape, executives must adopt a multifaceted strategy that balances innovation, operational excellence, and market agility. First, prioritizing investment in advanced delivery technologies can differentiate product offerings and enhance patient compliance. Deploying nanocarrier platforms or sustained-release implants, for example, can command premium positioning and reduce off-label competition. Second, strengthening supply chain resilience through dual sourcing strategies and nearshoring initiatives will mitigate the impact of import tariffs and geopolitical disruptions.

Third, forging collaborations with digital health providers can unlock real-world evidence on therapy outcomes and support value-based contracting discussions with payers. Fourth, tailoring go-to-market models to regional nuances-whether by partnering with local distributors in emerging economies or leveraging telehealth channels in mature markets-will optimize market penetration. Finally, embedding sustainability and environmental stewardship into manufacturing processes will not only meet regulatory expectations but also resonate with socially conscious stakeholders. By pursuing these imperatives in concert, industry leaders can capture growth opportunities, preempt competitive threats, and deliver measurable value to patients and investors alike.

Robust Methodology Underpinning Our Analysis

Our analysis is underpinned by a rigorous methodology designed to ensure accuracy, relevance, and comprehensiveness. We conducted exhaustive secondary research encompassing peer-reviewed journals, regulatory filings, and industry publications to establish a foundational understanding of clinical applications and technological trends. Primary interviews with senior stakeholders across pharmaceutical manufacturers, contract service providers, healthcare practitioners, and patient advocacy groups provided nuanced insights into market dynamics, unmet needs, and adoption barriers.

Quantitative data was triangulated through multiple sources, including import/export records, patent databases, and clinical trial registries, to validate trends in production volumes, pipeline activity, and therapeutic utilization. Segmentation hypotheses were tested using proprietary models that integrate demographic data, payer policies, and consumption patterns. Finally, our strategic analysis was subjected to peer review by domain experts to ensure that conclusions and recommendations reflect current realities and anticipated shifts. This robust framework delivers a high-confidence perspective on market opportunities, competitive positioning, and risk factors.

Concluding Insights on Progesterone Market Trajectory

In summary, the progesterone market stands at a pivotal juncture, shaped by technological innovations, evolving regulatory frameworks, and shifting patient expectations. The distinction between natural and synthetic formulations, coupled with diverse administration routes, underscores the importance of targeted strategies spanning R&D, manufacturing, and commercialization. Tariff adjustments in 2025 have introduced new cost and supply chain considerations, while regional dynamics continue to drive differentiated growth trajectories across the Americas, EMEA, and Asia-Pacific.

Competitive intensity is on the rise as legacy pharmaceutical giants, agile biotech firms, and specialized CDMOs vie for leadership through product innovation, strategic partnerships, and operational optimization. Success in this environment will depend on an integrated approach that leverages advanced delivery platforms, resilient sourcing strategies, and digital health integration. By aligning these capabilities with regional market nuances and end-user preferences, stakeholders can unlock new revenue streams and elevate standards of patient care. The insights presented in this executive summary equip decision-makers with the contextual understanding required to shape winning strategies and capitalize on the next wave of opportunities in the progesterone arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Natural Progesterone
    • Synthetic Progesterone
      • Medroxyprogesterone Acetate
      • Norethisterone
  • Indication
    • Contraceptives
      • Combined Oral Contraceptive
      • Progestin-Only Pill
    • Fertility Treatments
      • Assisted Reproductive Technology
      • Ovulation Induction
    • Hormone Replacement Therapy
      • Endometrial Protection
      • Menopause Management
  • Route Of Administration
    • Injectable
      • Intramuscular Injection
      • Subcutaneous Injection
    • Oral
    • Transdermal
    • Vaginal
      • Vaginal Gel
      • Vaginal Suppository
      • Vaginal Tablet
  • End User
    • Clinics
    • Home Healthcare
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • BASF SE
  • Merck KGaA
  • Balchem Corporation
  • Strides Pharma Science Limited
  • Gnosis S.p.A.
  • Caldic B.V.
  • Laboratoires Besins International
  • Ferring International Center S.A.
  • Teva Pharmaceutical Industries Ltd
  • Pharmascience Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Progesterone Market, by Product Type
8.1. Introduction
8.2. Natural Progesterone
8.3. Synthetic Progesterone
8.3.1. Medroxyprogesterone Acetate
8.3.2. Norethisterone
9. Progesterone Market, by Indication
9.1. Introduction
9.2. Contraceptives
9.2.1. Combined Oral Contraceptive
9.2.2. Progestin-Only Pill
9.3. Fertility Treatments
9.3.1. Assisted Reproductive Technology
9.3.2. Ovulation Induction
9.4. Hormone Replacement Therapy
9.4.1. Endometrial Protection
9.4.2. Menopause Management
10. Progesterone Market, by Route of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Intramuscular Injection
10.2.2. Subcutaneous Injection
10.3. Oral
10.4. Transdermal
10.5. Vaginal
10.5.1. Vaginal Gel
10.5.2. Vaginal Suppository
10.5.3. Vaginal Tablet
11. Progesterone Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Healthcare
11.4. Hospitals
12. Americas Progesterone Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Progesterone Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Progesterone Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. BASF SE
15.3.2. Merck KGaA
15.3.3. Balchem Corporation
15.3.4. Strides Pharma Science Limited
15.3.5. Gnosis S.p.A.
15.3.6. Caldic B.V.
15.3.7. Laboratoires Besins International
15.3.8. Ferring International Center S.A.
15.3.9. Teva Pharmaceutical Industries Ltd
15.3.10. Pharmascience Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. PROGESTERONE MARKET MULTI-CURRENCY
FIGURE 2. PROGESTERONE MARKET MULTI-LANGUAGE
FIGURE 3. PROGESTERONE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PROGESTERONE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PROGESTERONE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PROGESTERONE MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PROGESTERONE MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PROGESTERONE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PROGESTERONE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PROGESTERONE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PROGESTERONE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PROGESTERONE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PROGESTERONE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PROGESTERONE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PROGESTERONE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PROGESTERONE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PROGESTERONE MARKET SIZE, BY NATURAL PROGESTERONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PROGESTERONE MARKET SIZE, BY MEDROXYPROGESTERONE ACETATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PROGESTERONE MARKET SIZE, BY NORETHISTERONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PROGESTERONE MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PROGESTERONE MARKET SIZE, BY PROGESTIN-ONLY PILL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PROGESTERONE MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PROGESTERONE MARKET SIZE, BY OVULATION INDUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PROGESTERONE MARKET SIZE, BY ENDOMETRIAL PROTECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PROGESTERONE MARKET SIZE, BY MENOPAUSE MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PROGESTERONE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PROGESTERONE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PROGESTERONE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PROGESTERONE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL GEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL SUPPOSITORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PROGESTERONE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PROGESTERONE MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PROGESTERONE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES PROGESTERONE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. CANADA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 64. CANADA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 65. CANADA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. CANADA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 67. CANADA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 68. CANADA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 69. CANADA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. CANADA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 71. CANADA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 72. CANADA PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. MEXICO PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 77. MEXICO PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 79. MEXICO PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. MEXICO PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 81. MEXICO PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 82. MEXICO PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. GERMANY PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 125. GERMANY PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 126. GERMANY PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. GERMANY PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 128. GERMANY PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 129. GERMANY PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 130. GERMANY PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. GERMANY PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 132. GERMANY PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 133. GERMANY PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. FRANCE PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. FRANCE PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 136. FRANCE PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. FRANCE PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 138. FRANCE PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 139. FRANCE PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 140. FRANCE PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. FRANCE PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 142. FRANCE PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 143. FRANCE PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. ITALY PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 155. ITALY PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 156. ITALY PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. ITALY PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 158. ITALY PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 159. ITALY PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 160. ITALY PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. ITALY PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 162. ITALY PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 163. ITALY PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. SPAIN PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 165. SPAIN PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 166. SPAIN PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 167. SPAIN PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 168. SPAIN PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 169. SPAIN PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 170. SPAIN PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. SPAIN PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 172. SPAIN PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 173. SPAIN PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. UNITED ARAB EMIRATES PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 175. UNITED ARAB EMIRATES PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 176. UNITED ARAB EMIRATES PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. SAUDI ARABIA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. SAUDI ARABIA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 186. SAUDI ARABIA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. SOUTH AFRICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 195. SOUTH AFRICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. DENMARK PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 205. DENMARK PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 206. DENMARK PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 207. DENMARK PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 208. DENMARK PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 209. DENMARK PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 210. DENMARK PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. DENMARK PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 212. DENMARK PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 213. DENMARK PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. NETHERLANDS PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 215. NETHERLANDS PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 216. NETHERLANDS PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. QATAR PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 225. QATAR PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 226. QATAR PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 227. QATAR PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 228. QATAR PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 229. QATAR PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 230. QATAR PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. QATAR PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 232. QATAR PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 233. QATAR PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. FINLAND PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 235. FINLAND PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 236. FINLAND PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 237. FINLAND PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 238. FINLAND PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 239. FINLAND PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 240. FINLAND PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. FINLAND PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 242. FINLAND PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 243. FINLAND PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. SWEDEN PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 245. SWEDEN PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 246. SWEDEN PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. NIGERIA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. NIGERIA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 256. NIGERIA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 257. NIGERIA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. EGYPT PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 265. EGYPT PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 266. EGYPT PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 267. EGYPT PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 268. EGYPT PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 269. EGYPT PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 270. EGYPT PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. EGYPT PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 272. EGYPT PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 273. EGYPT PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. TURKEY PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 275. TURKEY PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 276. TURKEY PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 277. TURKEY PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 278. TURKEY PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 279. TURKEY PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 280. TURKEY PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. TURKEY PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 282. TURKEY PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 283. TURKEY PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. ISRAEL PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 285. ISRAEL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 286. ISRAEL PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 287. ISRAEL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. NORWAY PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 295. NORWAY PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 296. NORWAY PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 297. NORWAY PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 298. NORWAY PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 299. NORWAY PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 300. NORWAY PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. NORWAY PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 302. NORWAY PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 303. NORWAY PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. POLAND PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 305. POLAND PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 306. POLAND PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 307. POLAND PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 308. POLAND PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 309. POLAND PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 310. POLAND PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 311. POLAND PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 312. POLAND PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 313. POLAND PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 314. SWITZERLAND PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 315. SWITZERLAND PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 316. SWITZERLAND PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 317. SWITZERLAND PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 318. SWITZERLAND PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 319. SWITZERLAND PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 320. SWITZERLAND PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 321. SWITZERLAND PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 325. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 326. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 327. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 328. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 329. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 330. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 332. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 334. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 335. CHINA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 336. CHINA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 337. CHINA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 338. CHINA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 339. CHINA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 340. CHINA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 341. CHINA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 342. CHINA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 343. CHINA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 344. CHINA PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 345. INDIA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 346. INDIA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 347. INDIA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 348. INDIA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 349. INDIA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 350. INDIA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 351. INDIA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 352. INDIA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 353. INDIA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2030 (USD MILLION)
TABLE 354. INDIA PROGESTERONE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 355. JAPAN PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 356. JAPAN PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2030 (USD MILLION)
TABLE 357. JAPAN PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 358. JAPAN PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2030 (USD MILLION)
TABLE 359. JAPAN PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2030 (USD MILLION)
TABLE 360. JAPAN PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 361. JAPAN PROGESTERONE M

Companies Mentioned

The companies profiled in this Progesterone market report include:
  • BASF SE
  • Merck KGaA
  • Balchem Corporation
  • Strides Pharma Science Limited
  • Gnosis S.p.A.
  • Caldic B.V.
  • Laboratoires Besins International
  • Ferring International Center S.A.
  • Teva Pharmaceutical Industries Ltd
  • Pharmascience Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages193
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.68 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.15 Billion
Compound Annual Growth Rate13.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Progesterone ELISA Test Kits Market by Test Type (Direct ELISA, Indirect ELISA, Sandwich ELISA), Kit Type (Coated ELISA Kits, Uncoated ELISA Kits), End-user, Distribution Channel - Global Forecast 2025-2030 - Product Image

Progesterone ELISA Test Kits Market by Test Type (Direct ELISA, Indirect ELISA, Sandwich ELISA), Kit Type (Coated ELISA Kits, Uncoated ELISA Kits), End-user, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Progesterone - Global Strategic Business Report - Product Image

Progesterone - Global Strategic Business Report

  • Report
  • 74 Pages
  • Global
From
Progesterone Market 2024-2028 - Product Image

Progesterone Market 2024-2028

  • Report
  • 160 Pages
  • Global
From
Progesterone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Progesterone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Progesterone Receptor (PR) Antagonist - Pipeline Insight, 2025 - Product Image

Progesterone Receptor (PR) Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Progesterone Market

Progesterone is a hormone that plays an important role in women's health. It is produced by the ovaries and is essential for the regulation of the menstrual cycle, fertility, and pregnancy. Progesterone is also used to treat a variety of conditions, including abnormal uterine bleeding, endometriosis, and premenstrual syndrome. It is available in a variety of forms, including oral tablets, topical creams, and injections. The progesterone market is an important part of the women's health industry. It is driven by the increasing prevalence of conditions such as endometriosis and premenstrual syndrome, as well as the growing demand for hormone replacement therapy. The market is also influenced by the availability of new products and technologies, such as transdermal patches and vaginal rings. Some companies in the progesterone market include Pfizer, Merck, AbbVie, and Novo Nordisk. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.